Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Joly

Showing results (121-130 of 227) with videos related to

Pageof 23
Sort By:
The New England Journal of Medicine|February 1, 2002
A comparison of oral and topical corticosteroids in patients with bullous pemphigoidPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
The Oncologist|December 16, 2015
Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid PapulosisNadège Cordel, Benoît Tressières, Michel D'Incan, et al.
Archives of Dermatology|March 18, 2009
Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximabFlorent Grange, Eve Maubec, Martine Bagot, et al.
Journal of the American Academy of Dermatology|January 14, 2015
Association of occupational exposure with features of systemic sclerosisIsabelle Marie, Jean-François Menard, Anne-Bénédicte Duval-Modeste, et al.
Archives of Dermatology|September 21, 2005
Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective studyJulie de Quatrebarbes, Eric Estève, Martine Bagot, et al.
Frontiers in Immunology|April 4, 2022
The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With RituximabMarie-Laure Golinski, Alexandre Lemieux, Maud Maho-Vaillant, et al.
The British Journal of Dermatology|February 24, 2025
Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceusMaud Maho-Vaillant, Alexandre Lemieux, Christophe Arnoult, et al.
Science Translational Medicine|August 27, 2010
Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell responseDamien Picard, Baptiste Janela, Vincent Descamps, et al.
Frontiers in Immunology|June 6, 2022
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus FoliaceusMaud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, et al.
Clinical Case Reports|December 28, 2020
Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphomaBillal Tedbirt, Sydney Dubois, Lucie Cellier, et al.
Pageof 23

Showing results (121-130 of 227) with videos related to

Sort By:
Pageof 23
The New England Journal of Medicine|February 1, 2002
A comparison of oral and topical corticosteroids in patients with bullous pemphigoidPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
The Oncologist|December 16, 2015
Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid PapulosisNadège Cordel, Benoît Tressières, Michel D'Incan, et al.
Archives of Dermatology|March 18, 2009
Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximabFlorent Grange, Eve Maubec, Martine Bagot, et al.
Journal of the American Academy of Dermatology|January 14, 2015
Association of occupational exposure with features of systemic sclerosisIsabelle Marie, Jean-François Menard, Anne-Bénédicte Duval-Modeste, et al.
Archives of Dermatology|September 21, 2005
Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective studyJulie de Quatrebarbes, Eric Estève, Martine Bagot, et al.
Frontiers in Immunology|April 4, 2022
The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With RituximabMarie-Laure Golinski, Alexandre Lemieux, Maud Maho-Vaillant, et al.
The British Journal of Dermatology|February 24, 2025
Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceusMaud Maho-Vaillant, Alexandre Lemieux, Christophe Arnoult, et al.
Science Translational Medicine|August 27, 2010
Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell responseDamien Picard, Baptiste Janela, Vincent Descamps, et al.
Frontiers in Immunology|June 6, 2022
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus FoliaceusMaud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, et al.
Clinical Case Reports|December 28, 2020
Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphomaBillal Tedbirt, Sydney Dubois, Lucie Cellier, et al.
Pageof 23